Core Viewpoint - Furuya Medical Technology (01696.HK) announced a leadership change, with current Executive Director and Chairman Liu Yi transitioning to a non-executive director role effective January 1, 2026, while retaining membership in the nomination committee [1] Company Summary - As of December 8, 2025, Furuya Medical Technology's stock closed at HKD 4.16, down 0.95%, with a trading volume of 570,800 shares and a turnover of HKD 2.39 million [1] - The company has a market capitalization of HKD 1.967 billion, ranking 14th in the medical device II industry [1] Investment Ratings - The majority of investment banks have a "Buy" rating for the stock, with one bank issuing a "Buy" rating in the last 90 days [1] - Huaxi Securities provided a recent report recommending a "Buy" rating for Furuya Medical Technology [1] Key Financial Metrics - Return on Equity (ROE): 4.44%, compared to the industry average of -4.03%, ranking 13th [1] - Market capitalization in Hong Kong: HKD 1.967 billion, with the industry average at HKD 5.116 billion, ranking 14th [1] - Revenue: HKD 346 million, while the industry average is HKD 1.195 billion, ranking 21st [1] - Net Profit Margin: 5.43%, compared to the industry average of -16.5%, ranking 16th [1] - Gross Profit Margin: 60.04%, above the industry average of 54.89%, ranking 13th [1] - Debt Ratio: 22.99%, lower than the industry average of 29.03%, ranking 13th [1]
复锐医疗科技(01696.HK)：Lior Moshe DAYAN将出任执行董事、主席、提名委员会主席及授权代表